- Home
- LGMK vs XRTX Comparison
LGMK vs XRTX Comparison
Compare LGMK & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGMK
- XRTX
- Stock Information
- Founded
- LGMK 2011
- XRTX 2011
- Country
- LGMK United States
- XRTX Canada
- Employees
- LGMK N/A
- XRTX N/A
- Industry
- LGMK Industrial Specialties
- XRTX Pharmaceuticals and Biotechnology
- Sector
- LGMK Health Care
- XRTX Health Care
- Exchange
- LGMK Nasdaq
- XRTX Nasdaq
- Market Cap
- LGMK 3.5M
- XRTX 4.1M
- IPO Year
- LGMK N/A
- XRTX N/A
- Fundamental
- Price
- LGMK $1.41
- XRTX $1.00
- Analyst Decision
- LGMK
- XRTX
- Analyst Count
- LGMK 0
- XRTX 0
- Target Price
- LGMK N/A
- XRTX N/A
- AVG Volume (30 Days)
- LGMK 304.5K
- XRTX 278.9K
- Earning Date
- LGMK 11-12-2024
- XRTX 11-15-2024
- Dividend Yield
- LGMK N/A
- XRTX N/A
- EPS Growth
- LGMK N/A
- XRTX N/A
- EPS
- LGMK N/A
- XRTX N/A
- Revenue
- LGMK $10,078,502.00
- XRTX N/A
- Revenue This Year
- LGMK $1.54
- XRTX N/A
- Revenue Next Year
- LGMK N/A
- XRTX N/A
- P/E Ratio
- LGMK N/A
- XRTX N/A
- Revenue Growth
- LGMK 4.44
- XRTX N/A
- 52 Week Low
- LGMK $1.32
- XRTX $0.85
- 52 Week High
- LGMK $32.25
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- LGMK 38.44
- XRTX 36.68
- Support Level
- LGMK $1.32
- XRTX $0.85
- Resistance Level
- LGMK $1.49
- XRTX $1.79
- Average True Range (ATR)
- LGMK 0.15
- XRTX 0.19
- MACD
- LGMK 0.01
- XRTX -0.01
- Stochastic Oscillator
- LGMK 20.79
- XRTX 15.76
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.